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Introduction:  Replacing  live-attenuated  oral  poliovirus  vaccines  (OPV)  with  inactivated  poliovirus  vac-
cines (IPV)  is part  of  the  global  strategy  to  eradicate  poliomyelitis.  China  was  declared  polio-free  in 2000
but continues  to  record  cases  of vaccine-associated-poliomyelitis  and  vaccine-derived-poliovirus  out-
breaks. Two  pilot  safety  studies  and  two  larger immunogenicity  trials  evaluated  the  non-inferiority  of
IPV  (PoliorixTM, GSK  Vaccines,  Belgium)  versus  OPV in infants  and  booster  vaccination  in toddlers  primed
with  either  IPV or OPV  in  China.
Methods:  In  pilot  safety  studies,  25  infants  received  3-dose  IPV  primary  vaccination  (Study  A,  www.
clinicaltrial.gov NCT00937404)  and  25  received  an  IPV booster  after  priming  with  three  OPV doses
(Study  B,  NCT01021293).  In the  randomised,  controlled  immunogenicity  and  safety  trial (Study  C,
NCT00920439),  infants  received  3-dose  primary  vaccination  with  IPV  (N = 541)  or OPV  (N  =  535) at  2,3,4
months  of age,  and  a booster  IPV  dose  at  18-24  months  (N =  470,  Study  D,  NCT01323647:  extension  of
study  C).  Blood  samples  were  collected  before  and one  month  post-dose-3  and  booster.  Reactogenicity
was  assessed  using  diary  cards.  Serious  adverse  events  (SAEs)  were  captured  throughout  each  study.
Results: Study  A and  B  showed  that  IPV  priming  and  IPV boosting  (after OPV)  was  safe.  Study  C:  One
month  post-dose-3,  all IPV and ≥98.3%  OPV recipients  had  seroprotective  antibody  titres  towards  each
poliovirus  type.  The  immune  response  elicited  by  IPV  was  non-inferior  to  Chinese  OPV.  Seroprotective
antibody  titres  persisted  in  ≥94.7%  IPV and  ≥96.1%  OPV  recipients  at 18–24  months  (Study  D).  IPV  had  a
clinically  acceptable  safety  proﬁle  in  all studies.  Grade  3 local  and  systemic  reactions  were  uncommon.
No  SAEs  were related  to IPV  administration.
Conclusion:  Trivalent  IPV  is  non-inferior  to OPV  in  terms  of  seroprotection  (in  the  Chinese  vaccination
schedule)  in  infant  and  toddlers,  with  a clinically  acceptable  safety  proﬁle.
©  2016  The  Authors.  Publis
Abbreviations: CCID50, median cell culture infective dose; CI, conﬁdence inter-
al; D, Dalton units; DTP, diphtheria-tetanus-pertussis vaccine; DTPa/Hib, combined
iphtheria-tetanus-acellular pertussis and Haemophilus inﬂuenzae type b conju-
ate vaccine; GMT, geometric mean titres; Hib, Haemophilus inﬂuenzae type b; IPV,
nactivated poliovirus vaccines; OPV, oral live-attenuated oral poliovirus vaccines;
AE, serious adverse event; VAPP, vaccine associated paralytic poliomyelitis; WHO,
orld Health Organization.
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1. Introduction
Oral poliovirus vaccine (OPV) has been the mainstay of
poliomyelitis control in many countries since the 1950s. Nonethe-
less, there are several disadvantages in continuing vaccination
with OPV in countries where wild-type poliovirus has been erad-
icated. Despite its otherwise remarkable safety proﬁle, OPV may
rarely cause vaccine associated paralytic poliomyelitis (VAPP) due
to reverse mutations in the RNA genome of the attenuated vac-
cine strains resulting in neurovirulence [1]. An estimated two to
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
e 34 (2
f
e
o
b
O
t
g
e
o
m
h
a
P
t
2
d
c
[
A
b
t
s
t
H
a
t
u
r
r
W
h
o
i
o
a
i
d
4
s
D
i
a
i
2
a
s
H
l
e
e
t
G
f
D
C
f
CR. Li et al. / Vaccin
our VAPP cases per 1000,000 birth cohort are expected to occur
ach year in countries using OPV only [1]. In addition, outbreaks
f poliomyelitis caused by circulating vaccine-derived strains have
een documented and remain a potential threat in countries where
PV continues to be used [2,3].
Inactivated poliovirus vaccines (IPV) have been available since
he 1950s and enhanced IPV formulations with improved immuno-
enicity were introduced in the 1980s. The inactivation of IPV
nsures that reverse mutations and neurovirulence are unable to
ccur. IPV is highly immunogenic administered as IPV alone or in
ixed IPV-OPV schedules [4]. IPV manufactured by GSK Vaccines
as been used alone or in combination with diphtheria, tetanus
nd pertussis vaccine antigens since 1996 [5]. The standalone IPV
oliorixTM (hereafter referred to as IPV; GSK Vaccines, Belgium) con-
aining the three poliovirus types is currently licensed in more than
0 countries, and more than 12 million commercial doses have been
istributed. Routine use of IPV and IPV combination vaccines has
onﬁrmed their positive beneﬁt-risk proﬁle in developed countries
4,6].
In 2015, wild-type poliovirus 1 remains endemic in Pakistan and
fghanistan [7]. For the ﬁrst time, no wild-type polio cases have
een recorded in Africa for more than 12 months [7]. Poliomyeli-
is due to wild-type poliovirus type 2 has not been documented
ince 1999 and poliovirus type 3 since 2012. In anticipation of
he planned withdrawal of poliovirus type 2 from OPV, the World
ealth Organisation (WHO) recommends that all children receive
t least one IPV dose in order to maintain immunity to poliovirus
ype 2 [1]. In addition, the WHO  recommends that an all-IPV sched-
le be considered in countries with high vaccine coverage and a low
isk of importing wild virus [1].
In China, the last case of domestic wild-type poliomyelitis was
eported in 1994 and the country was certiﬁed as polio-free by
HO  in 2000. Since then, imported wild-type poliovirus outbreaks
ave been infrequently reported [8]. However, several outbreaks
f vaccine-derived poliovirus infections have been reported dur-
ng the last decade [2,3]. These outbreaks and the continuing risk
f VAPP in vaccinees highlight the need to consider the risks
ssociated with continued OPV use in the national poliomyelitis
mmunisation policy.
The Chinese poliomyelitis immunisation schedule comprises 3
oses of OPV at 2, 3 and 4 months of age, with one booster dose at
 years of age. We  conducted four clinical trials (two pilot safety
tudies: A and B, and a large randomised controlled study: C and
 (extension of study C) to assess the immunogenicity, reactogen-
city and safety of IPV when administered for primary vaccination
ccording to the Chinese immunisation schedule, and as a booster
n the second year of life.
. Methods
The study protocols and associated documents were reviewed
nd approved by the Guangxi Institutional Review Board. The
tudies were conducted in accordance with the Declaration of
elsinki, Good Clinical Practice principles and all applicable regu-
atory requirements. Written informed consent was obtained from
ach subject’s parent/legally acceptable representative prior to
nrolment.
Study A was conducted at the Cangwu Centre for Disease Con-
rol and Prevention, Longxu town, Cangwu County, Wuzhou City,
uangxi Province. Study B was conducted at the Wuzhou Centre
or Disease Control and Prevention, Wuzhou, Guangxi. Study C and were conducted in two centres: the Cangwu Centre for Disease
ontrol and Prevention in Wuzhou City and the Mengshan Centre
or Disease Control and Prevention, Mengshan Town, Mengshan
ounty.016) 1436–1443 1437
Studies A, B and C (NCT00937404, NCT01021293 and NCT-
00920439, respectively) were conducted between 04 August 2009
and 05 July 2010. Study D (NCT01323647) was  conducted between
23 April 2011 and 19 September 2011.
2.1. Study design and objectives
2.1.1. Pilot studies
Two  open, single group, pilot safety studies were conducted to
assess the safety and reactogenicity of IPV when administered as
a 3-dose primary vaccination in infants (Study A) and as a booster
dose in toddlers primed with three doses of OPV (Study B) (Table 1).
The sample sizes were chosen to provide at least 20 evaluable sub-
jects, as required by the Chinese Regulatory authority guidelines
[9].
2.1.2. Conﬁrmatory randomised controlled trial
Study C was  a randomised, controlled trial to assess the
immunogenicity, safety and reactogenicity of IPV when adminis-
tered in a 3-dose primary vaccination schedule. The primary study
objective was  to demonstrate non-inferiority of IPV as compared
to OPV in terms of the immune response to poliovirus types 1, 2
and 3 one month after the third vaccine dose (Table 1). A randomi-
sation list was generated at GSK Vaccines, Belgium and was used
to number the vaccines. Treatment allocation at the investigator
site was performed using a central, web-based randomisation sys-
tem. A blocking scheme ensured that balance between treatments
(1:1 ratio) was maintained. The randomisation algorithm used a
minimisation procedure accounting for centre [10].
Subjects vaccinated in Study C were invited to return at 18–24
months of age to participate in Study D in order to investigate
antibody persistence after primary vaccination with IPV or OPV
(Control group). Study D also assessed the immunogenicity, safety
and reactogenicity of a booster dose of IPV administered to children
who had received three priming IPV doses in Study C.
2.2. Participants
Participants in Study A and C were healthy infants between 60
and 90 days of age and born with a gestational age of 36 to 42
weeks. Participants in Study B and D were healthy toddlers 18 to
24 months of age. Toddlers participating in Study B had received
three priming doses of OPV in the ﬁrst year of life as per Chinese
recommendations. Toddlers participating in Study D had received
primary vaccination in Study C.
Infants and toddlers were excluded from participation if they
had evidence of previous or intercurrent poliomyelitis disease or
vaccination (other than the doses speciﬁed in the protocol of the
booster studies). Children were excluded if they had a history of
seizures or progressive neurological disease, any immunosuppress-
ive condition, a history of allergic reactions likely to be exacerbated
by any vaccine component, or major congenital defects or serious
chronic illness. Administration of a vaccine not foreseen by the
study protocol was not permitted within 30 days prior to vaccina-
tion, nor was  its planned administration during the study period;
with exception of combined diphtheria-tetanus-pertussis (DTP),
Haemophilus inﬂuenzae type b (Hib) conjugate vaccine and hepatitis
B vaccines. Children were excluded if they had received ≥14 days
of immunosuppressants or other immune-modifying drugs since
birth, immunoglobulins and/or any blood products since birth or
their planned administration during the study period.2.3. Vaccines and schedule
Each dose (0.5 ml)  of IPV contained 40 Dalton (D) antigen units
of inactivated poliovirus type 1, 8 D antigen units of inactivated
1438 R. Li et al. / Vaccine 34 (2016) 1436–1443
Table 1
Study design.
Study Age at
enrolment
Previous
vaccination
Study groups Schedule Objectives Outcome criteria
Study A
NCT00937404
60–90 days None IPV 2, 3, 4 months Reactogenicity, safety Descriptive
Study B
NCT00920439
18–24 months 3 doses of
OPV
IPV One dose
18–24 months
Reactogenicity, safety Descriptive
Study C
NCT01021293
60–90 days None IPV
OPV
2, 3, 4 months Immunogenicity,
reactogenicity, safety
Non-inferiority: the UL of the
95% CI on the difference
[Control group minus IPV
group] in the % of
seroprotected subjects is ≤10%
Study D
NCT01323647
18–24 months 3 doses of
IPV or OPV
in  Study C
IPV + DTPa/Hib
DTPa/Hib
One dose
18–24 months
Antibody persistence
(both groups)
Immunogenicity (IPV
group only)
Reactogenicity, safety
Exploratory analysis of
persistence: 95% CIs for the
GMT  ratio between groups
(Control group over IPV group)
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dPV = Inactivated poliovirus vaccine, OPV = Chinese live–attenuated oral poliovirus v
itre.
oliovirus type 2 and 32 D antigen units of inactivated poliovirus
ype 3, with 2-phenoxyethanol as preservative. One IPV vaccine
ot (AIPVB021B) was used for study A and B and a second lot
AIPVB023C) was used for Studies C and D. IPV was administered
ntramuscularly into the thigh using a 25 gauge needle of at least 1
nch (2.54 cm)  length.
The Chinese OPV vaccine (lot 20090401, administered to the
ontrol group in Study C) was cultured on Monkey Kidney Cells.
ach dose (2 drops, 0.1 ml)  contained a total amount of live virus
f ≥106.15 Median Cell Culture Infective Dose (CCID50), with ≥106.0
CID50 poliovirus type 1, ≥105.0 CCID50 poliovirus type 2 and ≥105.5
CID50 poliovirus type 3.
Primary vaccination with IPV or OPV was administered at 2, 3
nd 4 months of age (Studies A and C). Booster vaccination with
PV is not recommended under the Chinese vaccination schedule
ntil 4 years of age. Booster vaccination with IPV was  adminis-
ered at 18–24 months of age in Studies B and D. Children in study
 also received combined diphtheria-tetanus-acellular pertussis
nd Hib vaccine (DTPa/Hib, InfanrixTMHib, GSK Vaccines, Belgium),
o-administered at separate sites to IPV in the IPV group, and
dministered alone to the Control group.
.4. Safety evaluation (all studies)
The occurrence of redness, swelling, pain at the injection
ite, drowsiness, fever (axillary temperature >37.0 ◦C), irritabil-
ty/fussiness and loss of appetite that occurred within four days
day 0–3) after each dose were recorded on diary cards. Symptoms
ere graded on a 3-point scale where grade 3 (severe) was  deﬁned
s redness or swelling >30 mm,  fever >39.0 ◦C, ‘cried when limb was
oved/spontaneously painful’ for pain, drowsiness that ‘prevented
ormal activity’, ‘crying that could not be comforted/prevented
ormal activity’ for irritability/fussiness, and ‘did not eat at all’ for
oss of appetite. The occurrence of gastrointestinal symptoms was
dditionally solicited in Study C. Grade 3 gastrointestinal symptoms
nausea, vomiting, diarrhoea and/or abdominal pain) were deﬁned
s ‘preventing normal activity’.
All other adverse events including events that required med-
cal attention (deﬁned as hospitalisation or an unscheduled visit
o/from medical personnel, including emergency room visits) were
ecorded for each participant for 30 days after each vaccination (31-
ay follow up). Serious adverse events (SAEs) were captured from
he ﬁrst vaccination until one month after the last study vaccine
ose.(IPV group only)
e, IPV, DTPa/Hib, UL = Upper limit, CI = Conﬁdence interval, GMT  = Geometric mean
2.5. Immunogenicity evaluation (Study C and D)
Blood samples were collected from a subset of children (the ﬁrst
316 vaccinated in each group) before the ﬁrst dose and one month
post-dose 3 in Study C, from all children prior to booster vaccination
in Study D, and from all children in the IPV group in Study D one
month after the booster dose of IPV.
Serological assays were performed at the Chinese National Insti-
tute for Food and Drug Control laboratory in Beijing. Anti-poliovirus
type 1, 2 and 3 antibodies were measured using a virus micro-
neutralisation test adapted from the WHO  Guidelines for WHO/EPI
Collaborative Studies on Poliomyelitis [11]. The lowest dilution
tested was 1:8. Titres were expressed in terms of the reverse of
the 50% inhibitory dose. An antibody titre ≥8 was  considered sero-
protective.
3. Statistical analysis
Statistical analyses were performed using SAS® version 9.1 or
later on Windows XP Professional, and StatXact-7.0 or later proce-
dure on SAS.
The analyses of safety were performed on the Total vaccinated
cohorts, which comprised all children who  had received at least
one dose of the study vaccine. The analysis of immunogenicity
was conducted on the According-to-protocol (ATP) immunogenic-
ity cohort who comprised all eligible children who complied with
protocol-deﬁned procedures and for whom data concerning the
immunogenicity endpoint measures were available. The ATP per-
sistence cohort in Study D included all children who  had completed
their full 3-dose primary vaccination course in Study C, who  had
not received non-study polio vaccination and for whom serological
results were available at the persistence time point.
Seroprotection rates with exact 95% conﬁdence intervals (CI)
and geometric mean titres (GMTs) with 95% CIs were calculated for
each of the three poliovirus antigens at each time point. Antibody
titres below the cut-off of the assay were given an arbitrary value
of half the cut-off for the purpose of GMT  calculation.
One month after dose 3 in Study C, the standardised asymptotic
95% CIs for the group difference in seroprotection rates (Control
group minus IPV group) were computed. As agreed with the Chinese
Regulatory Agency, non-inferiority was concluded if the upper limit
of the 95% CI on the difference (Control group minus IPV group) in
the percentage of seroprotected subjects was ≤10%.
In exploratory analyses, the 95% CIs for the GMT  ratio between
groups (Control group over IPV group) for each of the three
poliovirus antigens were computed. In Study C the analysis
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sed an ANCOVA model including the vaccine group as ﬁxed
ffect and the log-transformed pre-vaccination titre as the co-
ariable. The ANCOVA model was selected because infants received
olio vaccination for the ﬁrst time, and the ANCOVA method
llowed adjustment for potentially variable pre-vaccination titres
‘adjusted GMTs’). In Study D, an ANOVA model on the logarithm10
ransformation of the titres prior to the booster dose was used as all
ubjects had receive primary vaccination against poliovirus. Poten-
ial differences were highlighted if the 95% CI for the GMT  ratio
etween groups did not contain the value ‘1′. Potential differences
hould be interpreted with caution as no adjustment for multiplic-
ty for these comparisons was accounted for in the planning of the
xploratory analyses.
To assess the impact of missing data due to children lost to
ollow-up on the results of Study D, a sensitivity analysis was per-
ormed using a general linear mixed model.
.1. Sample size
In order to meet Chinese Regulatory guideline requirements for
0 subjects, 25 infants and toddlers were enrolled in the pilot stud-
es (Study A and B).
With 284 children in the ATP immunogenicity cohort of each
roup in Study C, the study had 91% power to reach the primary
bjective assuming 90% seroprotection for each poliovirus type in
he Control group, with alpha equal to 2.5%. Assuming that approx-
mately 80% of these children participated in the extension study
nd that 10% would be non-evaluable, the expected 95% CI around
 post-booster seroprotection rate of 97.0% in 395 children would
e (94.8; 98.4).
. Results
.1. Pilot studies
25 children received at least one primary vaccination dose of IPV
n Study A, and 25 received a dose of IPV at 18–24 months of age in
tudy B, after OPV priming according to the Chinese recommended
chedule (Fig. 1).
Pain at the injection site was the most frequently reported
olicited local symptom after primary vaccination (Study A),
eported in 12.0% of children (Fig. 2). Irritability/fussiness was
he most frequently reported solicited general symptom (56% of
hildren). After the booster dose (Study B), the most frequently
eported solicited local and general symptoms were redness (20.0%
f children) and fever (24.0% of children). No grade 3 local or general
ymptoms were reported in either study.
At least one unsolicited symptom during the 31-day (day 0–30)
ollow-up period after vaccination was reported in 60% of children
n Study A and 40% of children in Study B. No grade 3 unsolicited
ymptoms and no SAEs were reported in either study.
.2. Conﬁrmatory studies
There were 1100 children who received primary vaccination
ith IPV or OPV in Study C. In Study D, a booster dose of IPV was
dministered to 470 children primed with IPV in Study C (Fig. 1).
here were a similar number of males and females in the IPV and
ontrol groups (Table 2).
.3. Safety.3.1. Primary vaccination
Pain at injection site was the most frequently reported solicited
ocal symptom after primary vaccination with IPV, reported in
0.5% of children in Study C (Fig. 2). Grade 3 pain was reported016) 1436–1443 1439
in 0.5% of children and grade 3 redness and swelling in 0.2% of
children.
Irritability/fussiness was  the most frequently reported solicited
general symptom in both groups (44.4% in the IPV group and 39.3%
in the Control group) (Fig. 2). The most frequently reported grade
3 symptom in both groups in Study C was irritability, reported in
1.8% and 1.6% of children in the IPV and Control group, respectively.
Grade 3 fever was uncommon (0.4% of children in the IPV group and
0.5% in the Control group).
At least one unsolicited symptom during the 31-day (day 0–30)
follow-up period after vaccination was reported in 28.2% (155/550)
of children in the IPV group and 29.5% (162/550) in the Control
group. Grade 3 symptoms were recorded in 0.7% (4/550) of children
in the IPV group (bronchitis, nasopharyngitis, upper respiratory
tract infection) and 0.5% (3/550) in the Control group (bronchitis,
upper respiratory tract infection). None of the grade 3 symptoms
were considered by the investigator to be causally related to vacci-
nation. At least one symptom (solicited or unsolicited) that required
medical attention was reported in 8.5% (47/550) of children in the
IPV group and 8.0% (44/550) of children in the Control group.
12 SAEs were recorded in nine children in Study C: three children
in the IPV group (diarrhoea, herpes zoster, hydrocephalus) and six
children in the Control group (bronchopneumonia, epilepsy, upper
respiratory tract infection, bronchitis, enteritis and in one child,
bronchopneumonia with abdominal distension, cardiac failure and
respiratory failure). There were no fatal events in any study. None
of the SAEs were considered by the investigator as causally related
to vaccination, and all had resolved by the end of the study.
4.3.2. Booster dose
After the booster IPV dose, the most frequently reported
solicited local symptom was  pain (10.5%) with a maximum inten-
sity of Grade 1 for 33 (7.1%) subjects (Fig. 2).
With the exception of fever, solicited general symptoms
appeared to be reported less frequently after the booster dose than
after primary vaccination (Fig. 2). The most frequently reported
solicited general symptom after the IPV booster was  fever (33.4%
of children). Grade 3 fever was  reported for eight children (1.7%).
At least one unsolicited symptom during the 31-day (day 0–30)
follow-up period after vaccination was reported in 4.7% (22/470) of
children in the IPV group. One grade 3 symptom (rash), reported in
one child (0.2%), was  considered by the investigator to be causally
related to vaccination. At least one symptom (solicited or unso-
licited) requiring medical attention was  recorded in 6.4% (30–470)
of children.
No SAEs were reported after booster vaccination with IPV in
Study D. One SAE (fever), reported for a child in the Control group,
was considered by the investigator as causally related to DTPa/Hib
vaccination.
4.4. Immunogenicity
4.4.1. Primary vaccination
Non-inferiority of the immune response elicited by IPV versus
Chinese OPV vaccine was  demonstrated according to the pre-
speciﬁed statistical criteria: the upper limit of the standardised
asymptotic 95% CI on the group difference for the percentage of
seroprotected subjects was  <10% for all poliovirus types (Table 3).
One month after the third dose, 100% of children in the IPV group
and at least 98.3% in the Control group had seroprotective anti-
body titres for each poliovirus type (Table 4). The anti-poliovirus
GMTs were 30 to 300 times higher than the seroprotection cut-off
in the two groups. Exploratory analyses suggested that the anti-
poliovirus type 1 and 2 GMTs were higher in the Control group
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*The  pa rent/ legal  gua rdian of one s ubject wi thd rew con sen t be fore randomisation  and  vaccination 
Study A
Primary vacc ination  with 
IPV at 2, 3, 4 mon ths
Study B
Boo ster vacc ination  with 
IPV at 18 -24  mon ths in 
OPV-primed todd lers
Study C: Primary vacc ination  with 
IPV or OPV at 2, 3, 4 mon ths 
N=1101 *
IPV grou p
Enrolled N=550
Compl eted N=53 8
Con trol grou p
Enrolled N=550
Compl eted N=52 6
Study D: Vacc ination  with IPV + 
DTPa/Hib or DTP/Hib alon e at 18 -24  
mon ths
9 withdrawals: Consent withdrawal (not 
due to an AE)  (5). Moved from stud y 
area  (2), lost to foll ow-up (2)
IPV grou p
Enroll ed N=47 0
Compl eted N=461
No withdrawals
Con trol grou p
Enroll ed N=48 7
Compl eted N=48 7
12 withd rawals: SAE (2), non-serious 
AE (2), Consent withd rawal (not du e to 
an AE)  (1). Moved from study area  (6), 
lost to foll ow-up  (1)
24 withd rawals: SAE (1), non-serious 
AE (1), Consent withd rawal (not du e to 
an AE)  (3). Move d from stud y area  
(18 ), lost to  foll ow-up  (1)
Total  vacc inated coh ort 
N=25
Total  vacc inated coho rt 
N=25
Two withd rawals: Consent 
withd rawal (not du e to an AE) . 
Violation of exclu sio n criteria  
(pre-existing  medical 
cond ition)
IPV group  
Enroll ed N=25
Compl eted N=23
One withd rawal: vacc ine not 
administered due to fever 
IPV group
Enroll ed N=26
Compl eted N=25
Total  vacc ina ted coho rt N=550  
ATP immunogenicity coho rt N=30 6
Total  vacc ina ted coho rt N=550  
ATP immunogenicity coho rt N=29 6
ATP persistence  coho rt N=47 0
Total  vacc ina ted coho rt N=470  
ATP immunogenicity coho rt N=45 6
ATP persistence  coho rt N=48 4
Fig. 1. Study ﬂow. * The parent/legal guardian of one subject withdrew consent before randomisation and vaccination. Note that blood samples were collected from a subset
of  children in Study C.
Table 2
Demographic features of participants.
Study A Study B Study C Study D
IPV  group IPV group IPV group Control group IPV group Control group
Total vaccinated cohorts
N 25 25 550 550 470 487
Age Mean (SD) 9.6 (1.4) wks 20.3 (1.5) mos  10.0 (1.2) wks 10.1 (1.2) wks 18.7 (0.9) mos  18.8 (1.0) mos
Range 8–12 18–23 8–12 8–12 18–22 18–22
Gender n (%) Female 15 (60) 13 (52.0) 268 (48.7) 259 (47.1) 234 (49.8) 227 (46.6)
Male  10 (40.0) 12 (48.0) 282 (51.3) 291 (52.9) 236 (50.2) 260 (53.4)
ATP  immunogenicity cohorts
N  306 296 456 –
Age  (weeks) Mean (SD) – – 10.1 (1.2) 10.0 (1.2) 18.7 (0.9) –
Range – – 8–12 8–12 18–22 –
Gender n (%) Female – – 146 (47.7) 140 (47.3) 227 (49.8) –
Male – – 160 (52.3) 156 (52.7) 229 (50.2) –
ATP  persistence cohort
N 470 484
Age  (weeks) Mean (SD) – – – – 18.7 (0.9) 18.8 (1.0)
Range – – – – 18–22 18–22
Gender n (%) Female – – – – 234 (49.8) 227 (46.9)
S
t
t
4
t
t
E
pMale  – – 
D = Standard deviation, ATP = According to protocol, wks = Weeks, mos  = Months.
han the IPV group, and were higher in the IPV group for poliovirus
ype 3 (Table 3).
.4.2. Antibody persistence
At 18–24 months of age the percentage of children with seropro-ective antibody titres was  at least 94.7% for each poliovirus type in
he IPV group, and at least 96.1% in the Control group (Table 4).
xploratory analyses continued to indicate that persisting anti-
oliovirus type 1 and 2 GMTs were higher in the Control group– – 236 (50.2) 257 (53.1)
than the IPV group, and were higher in the IPV group for poliovirus
type 3.
Results of the sensitivity analysis correcting for subjects lost
between the primary study and the persistence time point
showed that GMT  ratios calculated using the model were sim-
ilar to the observed GMT  ratios for all three polioviruses (data
not shown), indicating that subjects lost between the pri-
mary and the booster study did not affect the conclusions of
Study D.
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pig. 2. Solicited local and general symptoms reported within 4 days (Day 0–3) after 
PV  co-administered with DTPa/Hib. Therefore general symptoms cannot be clearly
.4.3. Booster vaccination
One month after the booster vaccination all children in the IPV
roup had seroprotective antibodies for each poliovirus. Antibody
MT  increased by at least 22-fold for each poliovirus, and post-
ooster GMTs were higher than those observed one month post-
rimary dose 3.
. Discussion
Three primary doses of IPV were immunogenic in children vac-
inated at 2, 3 and 4 months of age, with responses that were
on-inferior to Chinese OPV in terms of seroprotection. The major-
ty of children continued to have seroprotective antibodies for all
hree poliovirus types at 18–24 months of age, suggesting that IPV
nduced durable immunity. A booster dose of IPV elicited sero-
rotection in all subjects, as well as marked increases in GMTsation with IPV (or OPV) in four clinical trials. Note that children in Study D received
uted to either vaccine.
consistent with an immune memory response. We  observed lower
GMTs, but not seroprotection rates, for poliovirus types 1 and 2
in children who  received primary vaccination with IPV compared
to OPV. Lower GMTs were also observed following IPV-containing
than OPV-primary schedules in a recent study in Chinese infants
[12]. Similar trends were observed in studies conducted using other
IPV vaccines (alone or in combination) and schedules in other
countries including the United States [13]. This difference is likely
to be of little clinical importance in view of the high percentages
of children who  achieved the internationally-accepted seroprotec-
tive threshold [14], the large increases in titres observed after the
booster dose and because the GMTs are 30 to 300 times the assay
cut-off.
IPV was  well tolerated with few grade 3 local or general symp-
toms reported after vaccination. In the controlled Study C, the
occurrence of solicited general symptoms appeared to be similar
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Table 3
Group difference and ratios in the anti-poliovirus types 1, 2 and 3 antibodies response one month after the third dose of vaccination (Study C according-to-protocol cohort
for  immunogenicity).
IPV group (N = 306) Control group (N = 296)
Seroprotection rate (%) Difference in seroprotection rate (Control Group–IPV Group) % (95% CI)
Anti-poliovirus type 1 100 100 0.00 (−1.28; 1.24)
Anti-poliovirus type 2 100 100 0.00 (−1.28; 1.24)
Anti-poliovirus type 3 100 98.3 −1.69 (−3.90; −0.44)
Adjusted GMT  Adjusted GMT ratio Control/IPV value (95% CI)
Anti-poliovirus type 1 485.3 2815.9 5.80 (4.92; 6.84)
Anti-poliovirus type 2 232.8 471.5 2.03 (1.72; 2.38)
Anti-poliovirus type 3 824.1 423.5 0.51 (0.42; 0.63)
N = number of subjects with available results, % = percentage of subjects with titres ≥8 one month after the third dose, 95% CI for seroprotection = 95% standardised asymptotic
conﬁdence interval, 95% CI for GMT  ratio = 95% conﬁdence interval for the adjusted GMT  ratio (ANCOVA model: adjustment for pre vaccination titre—pooled variance).
Table  4
Anti-poliovirus seroprotection rates and GMTs in children who received primary vaccination with IPV or OPV, and booster vaccination with IPV (Study C and D According-
to-protocol cohorts for antibody persistence and immunogenicity).
Study group Time point N n %≥8 (95% CI) GMT (95% CI)
Poliovirus 1 IPV Pre 306 131 42.8 (37.2; 48.6) 8.7 (7.6; 9.8)
Post-3 306 306 100 (98.8; 100) 485.1 (436.7; 538.9)
Pre-B 470 462 98.3 (96.7; 99.3) 97.6 (87.3; 109.2)
Post-B 456 456 100 (99.2; 100) 3420.8 (3153.8; 3710.5)
Control Pre  296 113 38.2 (32.6; 44) 7.8 (6.9; 8.9)
Post-3 296 296 100 (98.8; 100) 2817.0 (2479.5; 3200.4)*
Pre-B 484 479 99 (97.6; 99.7) 533.0 (468.0; 607.0)*
Poliovirus 2 IPV Pre 306 93 30.4 (25.3; 35.9) 6.5 (5.9; 7.1)
Post-3 306 306 100 (98.8; 100) 234.3 (209; 262.6)
Pre-B 470 445 94.7 (92.2; 96.5) 87.8 (75.4; 102.2)
Post-B 456 456 100 (99.2; 100) 1886.8 (1732.7; 2054.5)
Control Pre  296 99 33.4 (28.1; 39.1) 7.2 (6.5; 8.1)
Post-3 296 296 100 (98.8; 100) 468.5 (416.6; 526.9)*
Pre-B 484 482 99.6 (98.5; 99.9) 205.5 (185.6; 227.5)*
Poliovirus 3 IPV Pre 306 48 15.7 (11.8; 20.3) 5.2 (4.8; 5.7)
Post-3 306 306 100 (98.8; 100) 824.3 (725.3; 936.9)*
Pre-B 470 446 94.9 (92.5; 96.7) 109.7 (94.2; 127.8)*
Post-B 456 456 100 (99.2; 100) 5097 (4706.8; 5519.6)
Control Pre  296 52 17.6 (13.4; 22.4) 5.2 (4.8; 5.7)
Post-3 296 291 98.3 (96.1; 99.4) 423.4 (363.3; 493.3)
Pre-B 484 465 96.1 (93.9; 97.6) 85 (76.1; 95.0)
N = number of children with available results, n/% = number (percentage) of children with titre ≥ speciﬁed value, 95% CI = 95% conﬁdence interval, Pre = before primary
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paccination, Post-3 = one month post-dose 3, Pre-B = prior to the booster dose, Post-
* For the exploratory analysis, 95% CI for the GMT  ratio between groups for the in
n the IPV and OPV groups. The incidence of fever was higher after
he booster dose of IPV than after primary vaccination, but grade 3
ever (>39 ◦C) was uncommon.
Study C and D provide IPV immunogenicity and safety data
n a large cohort of children compared with the recommended
hinese OPV vaccination schedule. A potential limitation of the
tudies is that safety of an IPV booster after OPV priming was  only
ssessed in a small cohort in pilot Study B, and immunogenicity of
n IPV booster after OPV priming was not evaluated. However, the
mmunogenicity and safety of IPV after OPV is well established, and
t least one dose of IPV after OPV priming is recommended by WHO
1].
The current Chinese schedule recommends a booster dose of
PV at 4 years of age. In view of the somewhat lower titres achieved
fter primary vaccination with IPV compared to OPV, as well as the
obust booster responses observed in our study after the 18–24
onth IPV booster dose, administration of the IPV booster dose in
he second year of life will help to ensure durable immunity against
oliovirus in an all-IPV schedule.
IPV has successfully controlled poliomyelitis in countries where
ts continuous and exclusive use has occurred; such as Iceland,
weden, Finland and the Netherlands. In the Netherlands and
weden, importation of wild-virus and occurrence of wild type
olio in unvaccinated religious groups has been successfullye month post booster.
d time point did not contain the value ‘1′ .
contained, demonstrating herd effects of IPV [15,16]. Impor-
tation of poliovirus type 1 to Israel (a sub-tropical country
that has used IPV exclusively since 2005) in 2013 resulted in
no cases of poliomyelitis, but evidence of transmission with
virus detected from environmental and stool samples [17]. The
long-term potential for continued poliovirus transmission in
settings of high faecal-oral transmission or in sub-tropical and
tropical settings where IPV is implemented exclusively is not
known.
The role of IPV in poliovirus control will continue to increase as
the world moves towards eradication [18]. This is reﬂected in WHO
guidelines that now recommend at least one IPV dose be admin-
istered to all children, and by the growing number of countries
transitioning from OPV to an all-IPV schedule [1]. As yet, success
of IPV in preventing poliovirus disease and transmission in devel-
oping countries and tropical settings has not been demonstrated.
The results of four studies in infants and toddlers suggest that IPV
is immunogenic with a clinically acceptable safety proﬁle when
administered at 2, 3, 4 and 18–24 months of age IPV could fea-
sibly be incorporated into Chinese vaccination schedule with the
advantage of eliminating the risk of VAPP and vaccine-derived
poliomyelitis outbreaks.
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